Goldman Sachs’s Scinai Immunotherapeutics SCNI Stock Holding History

Goldman Sachs’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-270	Closed	-$103K	–	6481
2021 Q1	$103K	Buy	+270	New	+$118K	﹤0.01%	5836

Other funds holding SCNI

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

TPWA

TRUE Private Wealth Advisors Salem, Oregon $1.05B AUM 19.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs's SCNI Position: Q2 2021 in Review

Goldman Sachs sold out of Scinai Immunotherapeutics (SCNI) in Q2 2021, closing a stake of 270 shares — an estimated $103K sold.

Goldman Sachs first reported a position in SCNI in Q1 2021 and held it in 1 quarter. The position peaked at $103K in Q1 2021. 16 funds tracked by Wall St. Rank hold SCNI as of Q2 2021.

Goldman Sachs reported no remaining Scinai Immunotherapeutics position as of Q2 2021 after selling out during the quarter.
Goldman Sachs sold 270 Scinai Immunotherapeutics shares in Q2 2021, an estimated $103K.
Goldman Sachs first reported a position in Scinai Immunotherapeutics in Q1 2021 and held it in 1 quarter.
Goldman Sachs's Scinai Immunotherapeutics position peaked at $103K in Q1 2021.
16 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2021.

Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.